We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform
Product News

Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform

Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform
Product News

Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform

Credit: Adj/rawpixel

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medidata, a company specializing in creating end-to-end solutions supporting the entire clinical trial process, has announced that it is collaborating with Moderna, Inc. to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

Medidata’s suite of technologies is supporting the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which is expected to enroll 30,000 participants. The Medidata and Moderna teams are moving forward with the speed and urgency necessitated by the global pandemic, using Medidata’s innovative and scalable cloud platform for clinical development.

This clinical trial is one of the largest ever to incorporate data capture directly from participants, decreasing the need for office visits. The “virtualization” of the study allows participants to use their own devices if they so choose, easing the burden of having to carry around a separate, provisioned device.

“We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society,” said Tarek Sherif, co-founder and co-CEO, Medidata. “The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”

“We are pleased to collaborate with Medidata,” said Marcello Damiani, Chief Digital and Operational Excellence Officer, Moderna. “Medidata’s unified platform is helping us put participants at the center of our efforts to develop a safe and effective vaccine against COVID-19.”

Moderna is using a suite of Medidata Rave technologies to help support and accelerate clinical development, including EDC (electronic data capture); eCOA (electronic clinical outcomes assessment), and Detect (centralized statistical monitoring). Moderna has been working with Medidata since December 2015 and the companies have collaborated on multiple clinical trials.

Advertisement